All articles tagged with #jnj
Johnson & Johnson will acquire Firefly Bio for $1 billion in cash to bolster its oncology pipeline with Firefly's Firelink degrader antibody conjugate (DAC) platform, designed to target KRAS-driven solid tumors by delivering selective protein degraders to cancer cells while sparing healthy tissue, with closing expected later this year pending regulatory approvals.
A $500,000 dividend-focused portfolio can generate about $17,500 a year at a 3.5% yield—enough to surpass the federal minimum wage—while higher yields offer more income but come with greater risk to principal. The article outlines three yield tiers (3-4%, 5-7%, 8-14%), citing SCHD and blue-chip dividends like JNJ and PG for steady growth, Realty Income for higher income, and warns that chasing yield can hurt long-term growth and complicate taxes. The core takeaway is to prioritize sustainable retirement income over chasing high yields, using a disciplined mix and considering total returns and tax impact.
Despite a pledge to improve U.S. manufacturing and overcome tariffs, Johnson & Johnson's stock performance has suffered, indicating challenges in its operational or market environment.